PL146301B1 - Method of obtaining phenyl carbaminates - Google Patents

Method of obtaining phenyl carbaminates Download PDF

Info

Publication number
PL146301B1
PL146301B1 PL1986258224A PL25822486A PL146301B1 PL 146301 B1 PL146301 B1 PL 146301B1 PL 1986258224 A PL1986258224 A PL 1986258224A PL 25822486 A PL25822486 A PL 25822486A PL 146301 B1 PL146301 B1 PL 146301B1
Authority
PL
Poland
Prior art keywords
formula
compound
compounds
group
lower alkyl
Prior art date
Application number
PL1986258224A
Other languages
English (en)
Polish (pl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL146301(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL146301B1 publication Critical patent/PL146301B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
PL1986258224A 1985-03-05 1986-03-04 Method of obtaining phenyl carbaminates PL146301B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (1)

Publication Number Publication Date
PL146301B1 true PL146301B1 (en) 1989-01-31

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL1986258224A PL146301B1 (en) 1985-03-05 1986-03-04 Method of obtaining phenyl carbaminates

Country Status (25)

Country Link
US (1) US4948807A (enExample)
EP (1) EP0193926B3 (enExample)
JP (1) JPS61225158A (enExample)
KR (1) KR940010764B1 (enExample)
AT (1) ATE58130T1 (enExample)
AU (1) AU595504B2 (enExample)
CA (1) CA1284501C (enExample)
CY (2) CY1748A (enExample)
DE (2) DE19875046I1 (enExample)
DK (1) DK172851B1 (enExample)
ES (1) ES8801193A1 (enExample)
FI (1) FI87197C (enExample)
GR (1) GR860586B (enExample)
HK (1) HK130293A (enExample)
HU (1) HU201297B (enExample)
IE (1) IE58838B1 (enExample)
IL (1) IL74497A (enExample)
LU (1) LU90312I2 (enExample)
MY (1) MY137602A (enExample)
NL (1) NL980031I2 (enExample)
NZ (1) NZ215348A (enExample)
PH (1) PH23325A (enExample)
PL (1) PL146301B1 (enExample)
PT (1) PT82127B (enExample)
ZA (1) ZA861653B (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DK0951284T3 (da) * 1996-12-18 2004-02-16 Teva Pharma Phenylethylminderivater
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
WO1998031356A1 (en) * 1997-01-17 1998-07-23 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
CN105112463A (zh) 2000-01-28 2015-12-02 Dsmip资产公司 通过在发酵罐中高密度培养真核微生物来增加含有多烯脂肪酸的脂质的产生
WO2001066114A1 (en) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US7385076B2 (en) 2002-05-31 2008-06-10 Sun Pharmaceutical Industries Limited Process for the preparation of phenylcarbamates
WO2003105830A1 (ja) 2002-06-14 2003-12-24 富山化学工業株式会社 脳機能を改善する医薬組成物および脳機能を改善するための方法
MXPA05003715A (es) 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP4676961B2 (ja) * 2003-10-21 2011-04-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類
US7671072B2 (en) 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
EP1718291A1 (en) * 2004-02-19 2006-11-08 Novartis AG Use of cholinesterase inhibitors for treating vascular depression
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
CN103142570A (zh) * 2005-12-09 2013-06-12 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil 用于神经保护的用途
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
BRPI0718437A2 (pt) 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
MX2009008288A (es) 2007-02-02 2009-12-01 Colucid Pharmaceuticals Inc Compuestos que inhiben la colinesterasa.
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US8852900B2 (en) 2010-06-17 2014-10-07 Codexis, Inc. Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
CA1284501C (en) 1991-05-28
EP0193926B3 (en) 2010-04-28
LU90312I2 (fr) 1999-01-06
US4948807A (en) 1990-08-14
IL74497A0 (en) 1985-06-30
DK172851B1 (da) 1999-08-16
FI87197B (fi) 1992-08-31
FI860914A0 (fi) 1986-03-04
ES552627A0 (es) 1988-01-01
CY1748A (en) 1994-06-03
IL74497A (en) 1990-02-09
EP0193926B1 (en) 1990-11-07
AU595504B2 (en) 1990-04-05
JPH0255416B2 (enExample) 1990-11-27
HUT41718A (en) 1987-05-28
DE19875046I1 (de) 2003-09-04
NL980031I2 (nl) 1999-03-01
HU201297B (en) 1990-10-28
PT82127A (en) 1986-04-01
GR860586B (en) 1986-07-07
ATE58130T1 (de) 1990-11-15
KR860007207A (ko) 1986-10-08
DE3675408D1 (de) 1990-12-13
HK130293A (en) 1993-12-03
IE58838B1 (en) 1993-11-17
NL980031I1 (nl) 1999-01-04
JPS61225158A (ja) 1986-10-06
NZ215348A (en) 1990-04-26
ES8801193A1 (es) 1988-01-01
CY2004004I1 (el) 2009-11-04
KR940010764B1 (ko) 1994-11-11
CY2004004I2 (el) 2009-11-04
IE860558L (en) 1986-09-05
PH23325A (en) 1989-07-14
AU5428486A (en) 1986-09-11
MY137602A (en) 2009-02-27
EP0193926A3 (en) 1987-05-13
EP0193926A2 (en) 1986-09-10
DK99186D0 (da) 1986-03-04
FI860914L (fi) 1986-09-06
PT82127B (pt) 1988-07-01
DK99186A (da) 1986-09-06
ZA861653B (en) 1987-10-28
FI87197C (fi) 1992-12-10

Similar Documents

Publication Publication Date Title
US4948807A (en) Phenyl carbamates
US5849737A (en) Compositions and methods for treating pain
RU2121346C1 (ru) Композиция, включающая вещество трамадол и ацетаминофен, и способ лечения с ее использованием
US5223541A (en) Tramadol n-oxide material, enantiomers and compositions thereof, and their use
EP2504311B1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
GB2152815A (en) Analgesic compositions
CA1315689C (en) Quarternary derivatives of noroxymorphone which relieve nausea and emesis
US20070105884A1 (en) Opiate analogs selective for the delta-opioid receptor
CA2641659A1 (en) 4-acylaminopyridine derivative mediated neurogenesis
US4352820A (en) Method for providing long-lasting local anesthesia and compounds and compositions therefore
EP1244498B1 (en) Combination of trimebutine with an opioid analgesic
DE3874982T2 (de) Antipsychotische zusammensetzungen mit dioxopiperidin-derivaten.
EP2790704B1 (en) Treatment of type i diabetes
Gesler et al. Further studies on the site of action of the neuromuscular blocking agent, 3, 6-bis (3-diethylaminopropoxy) pyridazine bismethiodide
US3670083A (en) Germine-diacetate in the treatment of myasthenia gravis
DE3390386T1 (de) Antitumor-Mittel, Verfahren zur Tumor-Therapie und Verwendung zur Tumor-Therapie
Hotelling POLYCYCLIC QUATERNARY AMMONIUM SALTS
WO2006096577A2 (en) Methods of preventing and treating opioid bowel dysfunction